Genentech Signs an Exclusive Option and License Agreement with Skyhawk to Discover and Develop RNA Splicing Modifiers for Oncology and Neurodegenerative Diseases
Shots:
- Skyhawk to receive up front- more than $2B as option fee & milestones- royalties on sales and will utilize its SkySTAR technology platform to discover and develop RNA splicing modifiers targeting oncology & neurological disorders
- Genentech to get an exclusive WW license to develop & commercialize RNA splicing modifiers targeting neurodegenerative diseases and cancer and will be responsible for clinical & commercial activities
- Skyhawk’s SkySTAR technology corrects the genetics of disease at the mRNA level in the nucleus of cells by integrating information from computational- kinetic- & structural models of RNA
Click here to read full press release/ article | Ref: PRNewswire | Image: Irish times
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com